Baxter International Inc
BAX: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$59.00 | Hkcjvrb | Rhjhrss |
After Strong Q1, Baxter Trims 2022 Outlook on Pump Delay and Supply Chain Issues; Shares Undervalued
Narrow-moat Baxter reported first-quarter profits that were better than anticipated. Despite these strong results, Baxter trimmed its guidance for 2022 on an expected delay in an infusion pump approval and supply chain concerns. Those factors only cut into our near-term assumptions for Baxter mildly, though, and we are maintaining our $90 fair value estimate. Baxter shares appear moderately undervalued to us.